12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cayston aztreonam lysine regulatory update

The Scottish Medicines Consortium recommended against the use of Cayston aztreonam from Gilead on the National Health Service (NHS) in Scotland to treat chronic pulmonary Pseudomonas aeruginosa infections in adult patients with cystic fibrosis -- its approved indication. The consortium said there are limited data to support the...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >